Search
News
Hudson Technologies Q2 2026 earnings: Higher volume could not protect margins
Hudson Technologies’ Q2 2026 revenue rose 8% to $78.3 million as sales volume increased 12%, but diluted EPS fell to $0.12 from $0.23. Gross margin declined to 26% from 31% as refrigerant prices fell 6% and fuel-related inflation raised operating costs, while SG&A increased to $12.4 million. The company ended June with $25.6 million in cash, reported negative $6.0 million operating cash flow for the first half, and lowered its full-year gross-margin target to the low-to-mid-20% range from the mid-20% range.
TradingKey
Wed, Aug 5
Legacy Housing Q2 2026 earnings: Workforce housing deliveries support 32% revenue growth
Legacy Housing (NASDAQ: LEGH) reported Q2 2026 net revenue of $66.3 million, up 32.3% year over year, and diluted EPS of $0.99, up 65.0%. Net income increased 59.8% to a record $23.5 million, while operating income rose 57.3% to $26.5 million. Growth was supported by the first 113 deliveries under a 380-unit workforce housing contract and strong shipments to other large customers. The remaining contracted units are expected to ship during the second half of 2026, making delivery execution a key area to monitor.
TradingKey
Wed, Aug 5
Sight Sciences Q2 2026 Earnings: Dry Eye Growth Supports Higher Revenue Guidance
Sight Sciences’ Q2 2026 revenue rose 20% year over year to $23.4 million, while GAAP net loss per share narrowed to $0.08 from $0.23. Interventional Dry Eye revenue reached a record $2.7 million, up 704%, as volume and average selling prices increased, while Interventional Glaucoma revenue grew 8% to $20.7 million. Reported gross margin was 91.4%, including a tariff-refund benefit, and cash usage fell 28% to $5.2 million. The company raised full-year revenue guidance to $88 million–$92 million and lowered adjusted operating expense guidance.
TradingKey
Wed, Aug 5
Remitly Q2 2026 Earnings: Revenue Rises 20% as Adjusted EBITDA Gains 79%
Remitly’s Q2 2026 revenue rose 20% year over year to $495.2 million as quarterly active customers reached 10.2 million and send volume climbed 27% to $23.5 billion. Adjusted EBITDA increased 79% to $114.7 million, while net income reached $205.9 million but included a $140.6 million discrete tax benefit. Quarterly free cash flow rose to $130.1 million. The company raised its fiscal 2026 outlook to revenue of $1.978 billion to $1.988 billion and adjusted EBITDA of $410 million to $415 million.
TradingKey
Wed, Aug 5
Trupanion Q2 2026 earnings: Subscription growth lifts operating profit
Trupanion (NASDAQ: TRUP) reported Q2 2026 revenue of $392.9 million, up 11% year over year, while diluted EPS declined to $0.16 from $0.22. Subscription revenue rose 14% to $276.7 million, helping operating income increase to $6.4 million and adjusted EBITDA reach $19.8 million. Free cash flow improved to $19.2 million. The quarter showed better underlying margins and continued subscription-pet growth, but total enrolled pets fell 2%, acquisition costs increased, and lower non-operating income caused GAAP net income to decline.
TradingKey
Wed, Aug 5
Encore Capital Q2 2026 Earnings: Record U.S. Collections Drive Revenue Growth
Encore Capital Group’s Q2 2026 revenue rose 11% to $491.9 million as global collections reached a record $736.9 million, up 13%. Diluted EPS increased 13% to $2.81, while net income rose 9% to $64.0 million despite a $30.5 million debt-refinancing charge. Record U.S. portfolio purchases and collections led performance, while European collections were flat. Encore revised full-year collections guidance to $2.80-$2.85 billion, maintained portfolio-purchase guidance of $1.4-$1.5 billion, and expects 2026 EPS of $13-$14.
TradingKey
Wed, Aug 5
Satellogic Q2 2026 earnings: Revenue rises 259% as operating income turns positive
Satellogic’s Q2 2026 revenue rose 259% to $15.9 million, while diluted loss per share widened to $0.13 from $0.06. The company posted its first positive operating income of $0.3 million and first positive adjusted EBITDA of $2.8 million, supported by Space Systems and Data & Analytics growth. GAAP net loss reached $20.0 million because of a $19.7 million non-cash fair-value charge. Cash ended the quarter at $112.8 million, adjusted operating cash flow was negative $0.3 million, and remaining performance obligations totaled $80.7 million.
TradingKey
Wed, Aug 5
PacBio Q2 2026 Earnings: Consumables Growth Could Not Prevent Margin Compression
PacBio reported Q2 2026 revenue of $39.0 million, down about 2% year over year, and a GAAP diluted loss of $0.14 per share, unchanged from Q2 2025. Consumables revenue rose 6% to $20.1 million and Revio placements increased to 20, but instrument revenue fell to $12.8 million and GAAP gross margin contracted to 32% from 37%. GAAP net loss widened to $44.7 million. The company’s FY2026 revenue outlook stands at $155 million to $165 million, making second-half execution and margin stabilization central issues.
TradingKey
Wed, Aug 5
OraSure Q2 2026 Earnings: A $22.6 Million Remeasurement Drove GAAP Profit
OraSure Technologies’ Q2 2026 revenue fell 2% year over year to $30.6 million, while diluted EPS improved to $0.09 from a $0.26 loss. GAAP gross margin rose to 43.5%, but a $22.6 million reduction in acquisition-related contingent consideration was the main reason the company reported $5.4 million of operating income. On a non-GAAP basis, operating loss widened to $14.7 million. Core revenue was essentially flat, cash stood at $160.6 million, and OraSure guided Q3 revenue to $29.5 million–$32.5 million. The quarter also brought FDA milestones alongside a revised CT/NG submission plan.
TradingKey
Wed, Aug 5
Inspired Q2 2026 Earnings: Portfolio Shift Lifts EBITDA Margin to 45%
Inspired Entertainment’s (NASDAQ: INSE) Q2 2026 revenue fell 24% year over year to $60.8 million after the UK holiday parks divestiture and pubs restructuring reduced the reported top line. Diluted EPS improved to $0.01 from a $0.27 loss, while net operating income rose 25% to $9.9 million. Adjusted EBITDA declined 5% to $27.1 million, but the adjusted EBITDA margin expanded to 45%. Interactive revenue grew 15%, and management reaffirmed its $112 million to $118 million full-year adjusted EBITDA target.
TradingKey
Wed, Aug 5
Standard BioTools Q2 2026 Earnings: Cost Cuts Narrow the Adjusted EBITDA Loss
Standard BioTools’ Q2 2026 revenue fell 7.6% to $20.1 million, while diluted loss per share from continuing operations widened to $0.06 from $0.05. GAAP gross margin rose to 52.4% from 48.8%, and the adjusted EBITDA loss narrowed to $2.5 million from $16.1 million as non-GAAP operating expenses fell 50%. However, $14.7 million of transaction and integration costs pushed the continuing-operations net loss to $21.5 million. The company withdrew its full-year revenue outlook while working toward completing the Treeline Biosciences merger before year-end 2026.
TradingKey
Wed, Aug 5
Emergent Q2 2026 earnings: MCM growth contrasts with NARCAN impairment
Emergent BioSolutions’ Q2 2026 revenue rose 66% to $234.3 million, while adjusted EBITDA increased to $96.5 million and adjusted diluted EPS reached $0.60. GAAP results moved the opposite way: a $191.3 million non-cash impairment tied to the NARCAN asset group pushed the company to a $180.2 million net loss. MCM product deliveries drove the quarter, but naloxone sales fell 22%, commercial margins contracted, and Emergent cut its full-year revenue, adjusted EBITDA and adjusted gross margin outlook while launching a restructuring expected to yield about $40 million in annualized savings.
TradingKey
Wed, Aug 5
SiTime Q2 2026 Earnings: Revenue More Than Doubles as Margins Expand
SiTime’s Q2 2026 revenue rose 127% year over year to $157.4 million, while GAAP diluted EPS improved to $0.66 from a $0.84 loss. GAAP gross margin expanded to 63.0%, and non-GAAP operating margin reached 34.0% as revenue grew faster than operating expenses. Every segment increased at least 50%, led by 181% growth in CED. The June 30 cash and short-term investment balance of $1.921 billion included convertible-note proceeds used for the Renesas Timing Business acquisition, which closed July 1 and was not part of the reported quarter.
TradingKey
Wed, Aug 5
Coca-Cola Consolidated Q2 2026 Earnings: Sales Rise as Margins Narrow
Coca-Cola Consolidated’s Q2 2026 net sales rose 10.6% to $2.05 billion, while diluted EPS increased to $2.38 from $2.15. Volume grew 7.6%, supported by broad portfolio gains, annual pricing, event-related demand and holiday timing. However, gross margin fell 210 basis points to 37.9% as elevated aluminum costs added about $45 million, leaving GAAP operating income nearly flat at $271.3 million. Net income declined 15.2% to $158.8 million amid non-cash fair-value adjustments and higher interest expense. First-half operating cash flow reached $420.6 million as the company made $275 million of early term-loan repayments.
TradingKey
Wed, Aug 5
Alto Ingredients Q2 2026 Earnings: Gross Margin Turns Positive
Alto Ingredients reported Q2 2026 net sales of $245.7 million, up 12.5% from $218.4 million, while diluted EPS swung to $0.15 from a $0.15 loss. Gross profit reached $16.6 million versus a $1.9 million loss, supported by higher alcohol pricing, lower average corn costs, and a sharp recovery at Pekin. Net income attributable to common stockholders was $11.4 million, and adjusted EBITDA rose to $23.7 million. A $5.1 million transferable tax-credit benefit also supported earnings, while the company added a $50 million at-the-market equity program.
TradingKey
Wed, Aug 5
Pennant Q2 2026 Earnings: Home Health and Hospice Drive 35.8% Revenue Growth
Pennant (NASDAQ: PNTG) reported Q2 2026 revenue of $298.0 million, up 35.8% year over year, and GAAP diluted EPS of $0.25 versus $0.20. Adjusted EBITDA increased 48.2% to $24.3 million, led by 43.2% growth in home health and hospice revenue. Same-agency results also advanced, but the gap versus total growth shows the importance of acquired operations. Pennant updated 2026 guidance to $1.171 billion-$1.190 billion in revenue and adjusted diluted EPS of $1.34-$1.41 as integration of its Southeast portfolio continues.
TradingKey
Wed, Aug 5
Mueller Water Products Q3 Fiscal 2026 Earnings: Pricing and Cost Control Expand Margins
Mueller Water Products (NYSE: MWA) reported fiscal Q3 2026 net sales of $395.9 million, up 4.1% year over year, while diluted EPS rose to $0.43 from $0.33. Adjusted EBITDA increased 24.3% to $107.4 million, lifting adjusted EBITDA margin by 440 basis points to 27.1%. Higher pricing, tariff refunds, and lower SG&A expenses outweighed slightly lower overall volumes and inflationary pressure. Water Management Solutions led segment growth, and the company raised fiscal 2026 adjusted EBITDA guidance to $367 million–$372 million while narrowing its sales outlook.
TradingKey
Wed, Aug 5
EZCORP Q3 FY2026 earnings: Revenue rises 35% as Latin America accelerates
EZCORP (NASDAQ: EZPW) reported fiscal third-quarter 2026 revenue of $418.7 million, up 35%, while GAAP diluted EPS rose 41% to $0.48. Net income attributable to EZCORP increased 44% to $38.2 million, and adjusted EBITDA advanced 48% to $65.6 million. Latin America Pawn led the operating gains, with segment contribution up 56%, while the newly consolidated SMG segment added $43.1 million of revenue. Pawn loans outstanding reached $387.2 million, but cash declined as the company retired SMG debt and funded acquisitions.
TradingKey
Wed, Aug 5
Vir Biotechnology Q2 2026 earnings: Astellas revenue drives a return to profit
Vir Biotechnology reported Q2 2026 revenue of $238.9 million, up from $1.2 million a year earlier, and diluted EPS of $0.47 versus a $0.80 loss. Net income reached $80.1 million, primarily driven by license and collaboration revenue tied to Astellas’ $240 million upfront payment. Cash, cash equivalents and investments ended June at approximately $1.01 billion, while R&D expense rose to $135.3 million. Key upcoming milestones include ECLIPSE 1 Phase 3 data in Q4 2026 and ECLIPSE 2 and 3 results in Q1 2027.
TradingKey
Wed, Aug 5
LifeMD Q2 2026 Earnings: GLP-1 Shift Lifts Gross Margin but Deepens Losses
LifeMD’s Q2 2026 revenue fell to $47.3 million from $49.0 million, while diluted loss per share from continuing operations widened to $0.16 from $0.09. Gross margin rose to about 89% from 86%, supported by lower shipping and fulfillment costs, provider efficiency, and scaling of the in-house pharmacy. However, adjusted EBITDA moved to a $3.5 million loss from $3.9 million of profit as the branded GLP-1 transition, customer acquisition costs, and lower upfront collections weighed on results. LifeMD also cut full-year revenue and adjusted EBITDA guidance.TradingKey
Wed, Aug 5
Featured Tools
Top News
Oracle Stock Forecast: $630 Billion AI Order Backlog Awaits Revaluation, Can the Stock Continue to Recover?
Micron vs. SK Hynix: As HBM Demand Continues to Surge, Which Memory Stock Deserves More Attention?
New CEO Ternus Launches iPhone 18 Pro on September 9 — Can Apple Reverse Q3 China Miss Before Jackson Hole?
Micron Stock Forecast: Can AI Memory Demand Push MU Above $1,000?
The Week Ahead: Fed Minutes, Walmart, Target and Home Depot Earnings to Test US Consumer Resilience
